Flubendazole reduces cell growth and viability in malignant cells
| Cell line . | Flubendazole, μM . | Colchicine, nM . | Vinblastine, μM . |
|---|---|---|---|
| KB-3-1 | 1.9 ± 1.1 | 14.9 ± 4.5 | |
| KB-4.0-HTI | 12.5 ± 1.8 | 41.6 ± 5.5 | |
| A549 | 4.1 ± 1.3 | 0.09 ± 0.01 | |
| A549.EpoB40 | 0.8 ± 0.2 | 0.06 ± 0.01 | |
| CEM | 1.9 ± 0.9 | 0.14 ± 0.01 | |
| CEM-VBL | 2.7 ± 1.2 | > 5.0 |
| Cell line . | Flubendazole, μM . | Colchicine, nM . | Vinblastine, μM . |
|---|---|---|---|
| KB-3-1 | 1.9 ± 1.1 | 14.9 ± 4.5 | |
| KB-4.0-HTI | 12.5 ± 1.8 | 41.6 ± 5.5 | |
| A549 | 4.1 ± 1.3 | 0.09 ± 0.01 | |
| A549.EpoB40 | 0.8 ± 0.2 | 0.06 ± 0.01 | |
| CEM | 1.9 ± 0.9 | 0.14 ± 0.01 | |
| CEM-VBL | 2.7 ± 1.2 | > 5.0 |
KB-4.0-HTI cells with an α-tubulin mutation and KB-3-1 wild-type controls, A549.EpoB40 cells with a β-tubulin mutation and the A549 wild-type controls, and CEM VBL cells overexpressing P-glycoprotein and CEM wild-type controls were treated with increasing concentrations of flubendazole for 72 hours. Data represent IC50 values, as measured by the MTS assay.